中重度稳定期COPD患者血清DcR3与气流限制、生活质量和1年内急性发作的相关性

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1365 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨中重度稳定期慢性阻塞性肺病(COPD)患者的血清诱饵受体3(DcR3)水平,并研究DcR3与气流受限、生活质量和1年内急性发作的相关性。方法选取2021-08至2022-08空军第986医院诊治的81例中重度稳定期COPD患者作为研究对象,采用酶联免疫吸附法测量血清DcR3水平,并使用Spearman相关性分析血清DcR3与气流限制和生活质量的相关性,二元logistic回归分析影响1年内急性发作的临床因素,受试者工作特征(ROC)曲线分析血清DcR3预测1年内急性发作的临床价值。结果与血清DcR3≥2.45 ng/ml(中位值)组比较,血清DcR3＜2.45 ng/ml组嗜碱性粒细胞计数显著升高(P＜0.05),1年内急性发作次数和住院次数显著减少(P＜0.05)。血清DcR3与第一秒用力呼气容积(FEV₁)(r=－0.389)、FEV₁/用力肺活量(FVC)(r=－0.610)、一氧化碳弥散量(r=－0.611)、吸气量(IC)/肺总量比值(TLC)(r=－0.862)呈负相关性,P均＜0.05。血清DcR3与COPD评估试验(CAT)(r=0.638)、视觉模拟量表(VAS)-咳嗽(r=0.282)、VAS-咳痰(r=0.269)、VAS-脓痰(r=0.237)评分呈正相关性,P＜0.05。白细胞介素(IL)-6与被检者75%的最大呼气流速(r=－0.481)呈负相关,C反应蛋白(CRP)与CAT评分(r=0.521)呈正相关(P＜0.05)。经二元logistic回归,血清DcR3与COPD1年内急性发作独立相关(P＜0.05)。血清DcR3预测COPD患者1年内急性发作的曲线下面积为[0.788(95%CI:0.688～0.888)],当血清DcR3≥2.435 ng/ml时,灵敏度(0.689)和特异度(0.833)最高。结论 COPD患者中血清DcR3与气流受限、生活质量、疾病严重程度,以及1年内急性发作有关,血清DcR3水平有作为COPD患者发病机制标志物的潜力。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	郭丽
	谢柏梅
	王娟

关键词 ：慢性阻塞性肺病, 诱饵受体3, 气流限制, 生活质量, 急性发作

Abstract：Objective To investigate the serum Decoy Receptor 3 (DcR3) level in patients with chronic obstructive pulmonary disease (COPD) and to investigate the correlation of DcR3 with airflow restriction, quality of life and acute exacerbations within 1 year. Methods From August 2021 to August 2022, 81 patients with moderate to severe COPD were included as study subjects. Serum DcR3 levels were measured by enzyme-linked immunosorbent assay, and the correlation of serum DcR3 with airflow restriction and quality of life was analyzed by Spearman correlation analysis. The clinical factors influencing acute exacerbations within 1 year were analyzed by binary Logistic regression, and the clinical value of serum DcR3 in predicting acute exacerbations within 1 year was analyzed by receiver operating characteristic (ROC) curve. Results Compared with the serum DcR3≥2.45 ng/ml (median) group, the basophil count in the serum DcR3<2.45 ng/ml group significantly increased (P<0.05), and the number of acute exacerbation and hospitalizations within 1 year significantly decreased (P<0.05). Serum DcR3 was negatively correlated with forced expiratory volume in the first second (FEV₁) (r=-0.389), FEV1/forced vital capacity (FVC) (r=-0.610), diffusing capacity of the lungs for carbon monoxide (r=-0.611), and inspiratory volume (IC)/total lung ratio (TLC) (r=-0.862), all P<0.05. There was a positive correlation between serum DcR3 and COPD assessment test (CAT) (r=0.638), visual analogue scale (VAS)-cough (r=0.282), VAS-sputum (r=0.269) and VAS-purulent sputum (r=0.237) scores, all P<0.05. Interleukin (IL)-6 was negatively correlated with 75% of the maximum expiratory flow rate (r=-0.481), and C-reactive protein (CRP) was positively correlated with CAT score (r=0.521), both P<0.05. By binary logistic regression, serum DcR3 was independently correlated with acute exacerbations of COPD within one year (P<0.05).The area under the curve of serum DcR3 in predicting acute exacerbations in COPD patients within 1 year was [0.788 (95%CI: 0.688～0.888)], and the sensitivity (0.689) and specificity (0.833) were the highest when serum DcR3≥2.435 ng/ml. Conclusions Serum DcR3 is associated with airflow restriction, quality of life, disease severity and acute onset within 1 year in COPD patients, and serum DcR3 level has potential as a marker of pathogenesis of COPD patients.

Key words： chronic obstructive pulmonary disease decoy receptor 3 airflow restriction quality of life acute exacerbation

收稿日期: 2024-03-29

ZTFLH:

R563

基金资助:陕西省自然科学基金研究计划项目(2022JQ-751)

通讯作者: 王娟,E-mail:ddys1211@163.com

作者简介: 郭丽,硕士,主治医师。

引用本文:

郭丽, 谢柏梅, 王娟. 中重度稳定期COPD患者血清DcR3与气流限制、生活质量和1年内急性发作的相关性[J]. 武警医学, 2024, 35(9): 770-776. GUO Li, XIE Baimei, WANG Juan. Correlation between serum decoy receptor 3 and airflow restriction, quality of life, and exacerbations within 1 year in patients with moderate to severe stable COPD. Med. J. Chin. Peop. Armed Poli. Forc., 2024, 35(9): 770-776.

链接本文:

https://journal08.magtechjournal.com/Jwk_wjyx/CN/ 或 https://journal08.magtechjournal.com/Jwk_wjyx/CN/Y2024/V35/I9/770

[1]	Aslani M R, Ghazaei Z, Ghobadi H. Correlation of serum fatty acid binding protein-4 and interleukin-6 with airflow limitation and quality of life in stable and acute exacerbation of COPD[J]. Turk J Med Sci, 2020, 50(2): 337-345.
[2]	Owusuaa C, Leest C, Helfrich G, et al. The development of the ADO-SQ model to predict 1-year mortality in patients with COPD[J]. Palliat Med, 2022, 36(5): 821-829.
[3]	刘雯, 费维伦, 梁春阳, 等. 血清DcR3对COPD急性加重期患者预后评估的应用价值[J]. 中国急救复苏与灾害医学杂志,2022,17(2):225-229.
[4]	Kamal A, Abdelmegeid A K, Gabr M A, et al. Serum decoy receptor 3 (DcR3): a promising biomarker for atopic asthma in children[J]. Immunol Res, 2021, 69(6): 568-575.
[5]	中华医学会呼吸病学分会慢性阻塞性肺疾病学组, 中国医师协会呼吸医师分会慢性阻塞性肺疾病工作委员会. 慢性阻塞性肺疾病诊治指南(2021年修订版)[J]. 中华结核和呼吸杂志, 2021,44(3) : 170-205.
[6]	夏君燕, 张英, 高永红. 老年COPD急性加重期患者血清miR-448-5p、Six1水平及其临床意义[J]. 国际检验医学杂志,2023,44(14):1737-1742.
[7]	黄长明, 吴瑕, 张冉, 等. COPD急性加重期患者血清SIRT1与炎症因子水平的相关性及临床意义[J]. 中南医学科学杂志,2023,51(6):931-933.
[8]	Brightling C, Greening N. Airway inflammation in COPD: progress to precision medicine[J]. Eur Respir J, 2019, 54(2): 1900651-1900663.
[9]	Xue Q, Xie Y, He Y, et al. Lung microbiome and cytokine profiles in different disease states of COPD: a cohort study[J]. Sci Rep, 2023, 13(1): 5715-5725.
[10]	陈灿, 郑林鑫, 麦玉梅, 等. 慢性阻塞性肺疾病并骨质疏松患者血清IL-6、TNF-α水平的变化及其对OPG、RANKL表达的影响[J]. 临床肺科杂志,2023,28(1):35-38.
[11]	胡斯育, 杨浩军, 杨凡,等. 维生素D对COPD稳定期患者血清TNF-α、IL-6及肺功能的影响[J]. 湖南师范大学学报(医学版),2019,16(3):38-40.
[12]	Su J, Tong Z, Wu S, et al. Research Progress of DcR3 in the diagnosis and treatment of sepsis[J]. Int J Mol Sci, 2023, 24(16): 12916-12930.
[13]	谷丽华, 贺晶晶, 袁佳健, 等. DCR3、CRP/Alb、Trx与细菌性肝脓肿并发感染性休克的相关性[J]. 肝脏,2023,28(10):1227-1230,1256.
[14]	龚峰, 张莉, 周莉. 血清endocan、DcR3与支气管哮喘患儿气道炎症的关系[J]. 国际检验医学杂志,2024,45(2):165-169.
[15]	侯丽娟, 王文文, 翟建军, 等. 血清HIF-1α、DcR3、TSGF在宫颈癌诊断中的作用及其与患者临床病理参数的关系[J]. 山东医药,2021,61(11):52-55.
[16]	邢燕平, 任红娟, 王欣. 诱骗受体3(DcR3)与人上皮卵巢癌患者预后的关系[J]. 实用癌症杂志,2022,37(5):736-738.
[17]	赵佳媛, 许婷婷, 吴笛, 等. DcR3 ALB水平与慢阻肺急性加重期合并呼衰患者转归关系[J]. 河北医学,2021,27(9):1436-1440.
[18]	刘敏,王立芹, 杨茂勇, 等. 血清肿瘤坏死因子受体-6水平对AECOPD合并呼吸衰竭患者转归的影响.中国医师杂志,2019,21(8):1181.
[19]	Ghobadi H, Hosseini N, Aslani M R. Correlations between serum decoy receptor 3 and airflow limitation and quality of life in male patients with stable stage and acute exacerbation of COPD[J]. Lung, 2020, 198(3): 515-523.